BPI-28592

BPI-28592 is a novel, second-generation small molecule inhibitor targeting tropomyosin receptor kinases (TRKs), specifically TRKA, TRKB, and TRKC. It is designed to treat cancers harboring neurotrophic tropomyosin receptor kinase (NTRK) gene fusions, including those with acquired resistance mutations to first-generation TRK inhibitors. Preclinical studies demonstrate that BPI-28592 exhibits strong inhibition and high selectivity for all three TRK isoforms, effectively blocking downstream signaling and reducing cell proliferation in vitro. In vivo xenograft models show significant tumor suppression in both wild-type and resistant NTRK fusion-positive tumors. Clinically, the drug has shown promising activity; notably achieving a complete response in a patient with malignant melanoma carrying an AP3S2-NTRK3 fusion. The drug is currently being evaluated in Phase 1 clinical trials for advanced solid tumors[1][2][6].